Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1987 May;84(9):2911–2915. doi: 10.1073/pnas.84.9.2911

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

P O Livingston, E J Natoli, M J Calves, E Stockert, H F Oettgen, L J Old
PMCID: PMC304770  PMID: 3472242

Abstract

GM2, GD2, and GD3 gangliosides are expressed on the surface of human melanoma cells and represent potential targets for immunological control of melanoma growth by monoclonal antibodies and active immunization. The immunogenicity of GM2 was investigated by analyzing the humoral immune response of melanoma patients to vaccination with cell lines selected for high GM2 expression and with vaccines containing purified GM2. The whole-cell vaccine and vaccines containing purified GM2 and bacillus Calmette-Guérin (BCG) elicited GM2 antibody in a high proportion of patients, particularly in GM2/BCG-vaccinated patients pretreated with cyclophosphamide and given a GM2/BCG booster immunization. Vaccines containing purified GM2 and Salmonella minnesota R595 as the adjuvant were also effective, but only in patients pretreated with cyclophosphamide. GM2 antibodies in vaccinated patients were of the IgM class and were cytotoxic for GM2-positive targets in the presence of human complement.

Full text

PDF
2911

Images in this article

2913Image
on p.2913
2913Image
on p.2913

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnon R., Crisp E., Kelley R., Ellison G. W., Myers L. W., Tourtellotte W. W. Anti-ganglioside antibodies in multiple sclerosis. J Neurol Sci. 1980 May;46(2):179–186. doi: 10.1016/0022-510x(80)90076-3. [DOI] [PubMed] [Google Scholar]
  2. Berkelhammer J., Oxenhandler R. W., Hook R. R., Jr, Hennessy J. M. Development of a new melanoma model in C57BL/6 mice. Cancer Res. 1982 Aug;42(8):3157–3163. [PubMed] [Google Scholar]
  3. Cahan L. D., Irie R. F., Singh R., Cassidenti A., Paulson J. C. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7629–7633. doi: 10.1073/pnas.79.24.7629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cheresh D. A., Harper J. R., Schulz G., Reisfeld R. A. Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci U S A. 1984 Sep;81(18):5767–5771. doi: 10.1073/pnas.81.18.5767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cheresh D. A., Klier F. G. Disialoganglioside GD2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin. J Cell Biol. 1986 May;102(5):1887–1897. doi: 10.1083/jcb.102.5.1887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cheung N. K., Saarinen U. M., Neely J. E., Landmeier B., Donovan D., Coccia P. F. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985 Jun;45(6):2642–2649. [PubMed] [Google Scholar]
  7. Cochran F. B., Jr, Yu R. K., Ledeen R. W. Myelin gangliosides in vertebrates. J Neurochem. 1982 Sep;39(3):773–779. doi: 10.1111/j.1471-4159.1982.tb07959.x. [DOI] [PubMed] [Google Scholar]
  8. Dippold W. G., Lloyd K. O., Li L. T., Ikeda H., Oettgen H. F., Old L. J. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A. 1980 Oct;77(10):6114–6118. doi: 10.1073/pnas.77.10.6114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Galanos C., Lüderitz O., Westphal O. Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides. Eur J Biochem. 1971 Dec 22;24(1):116–122. doi: 10.1111/j.1432-1033.1971.tb19661.x. [DOI] [PubMed] [Google Scholar]
  10. Houghton A. N., Brooks H., Cote R. J., Taormina M. C., Oettgen H. F., Old L. J. Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma. J Exp Med. 1983 Jul 1;158(1):53–65. doi: 10.1084/jem.158.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Knuth A., Danowski B., Oettgen H. F., Old L. J. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A. 1984 Jun;81(11):3511–3515. doi: 10.1073/pnas.81.11.3511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Livingston P. O., Albino A. P., Chung T. J., Real F. X., Houghton A. N., Oettgen H. F., Old L. J. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer. 1985 Feb 15;55(4):713–720. doi: 10.1002/1097-0142(19850215)55:4<713::aid-cncr2820550407>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  13. Livingston P. O., Calves M. J., Natoli E. J., Jr Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells. J Immunol. 1987 Mar 1;138(5):1524–1529. [PubMed] [Google Scholar]
  14. Livingston P. O., DeLeo A. B., Jones M., Oettgen H. F. Comparison of approaches for augmenting the serologic response to the individually specific methylcholanthrene-induced sarcoma-Meth A: pretreatment with cyclophosphamide is most effective. J Immunol. 1983 Nov;131(5):2601–2605. [PubMed] [Google Scholar]
  15. Livingston P. O., Jones M., Deleo A. B., Oettgen H. F., Old L. J. The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants. J Immunol. 1985 Aug;135(2):1505–1509. [PubMed] [Google Scholar]
  16. Livingston P. O., Kaelin K., Pinsky C. M., Oettgen H. F., Old L. J. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines. Cancer. 1985 Nov 1;56(9):2194–2200. doi: 10.1002/1097-0142(19851101)56:9<2194::aid-cncr2820560910>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  17. Livingston P. O., Shiku H., Bean M. A., Pinsky C. M., Oettgen H. F., Old L. J. Cell-mediated cytotoxicity for cultured autologous melanoma cells. Int J Cancer. 1979 Jul 15;24(1):34–44. doi: 10.1002/ijc.2910240107. [DOI] [PubMed] [Google Scholar]
  18. Livingston P. O., Takeyama H., Pollack M. S., Houghton A. N., Albino A., Pinsky C. M., Oettgen H. F., Old L. J. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Int J Cancer. 1983 May 15;31(5):567–575. doi: 10.1002/ijc.2910310507. [DOI] [PubMed] [Google Scholar]
  19. Livingston P. O., Watanabe T., Shiku H., Houghton A. N., Albino A., Takahashi T., Resnick L. A., Michitsch R., Pinsky C. M., Oettgen H. F. Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells. Int J Cancer. 1982 Oct 15;30(4):413–422. doi: 10.1002/ijc.2910300406. [DOI] [PubMed] [Google Scholar]
  20. Natoli E. J., Jr, Livingston P. O., Pukel C. S., Lloyd K. O., Wiegandt H., Szalay J., Oettgen H. F., Old L. J. A murine monoclonal antibody detecting N-acetyl- and N-glycolyl-GM2: characterization of cell surface reactivity. Cancer Res. 1986 Aug;46(8):4116–4120. [PubMed] [Google Scholar]
  21. Nudelman E., Hakomori S., Kannagi R., Levery S., Yeh M. Y., Hellström K. E., Hellström I. Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2. J Biol Chem. 1982 Nov 10;257(21):12752–12756. [PubMed] [Google Scholar]
  22. Old L. J. Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. Cancer Res. 1981 Feb;41(2):361–375. [PubMed] [Google Scholar]
  23. Pukel C. S., Lloyd K. O., Travassos L. R., Dippold W. G., Oettgen H. F., Old L. J. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med. 1982 Apr 1;155(4):1133–1147. doi: 10.1084/jem.155.4.1133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Real F. X., Mattes M. J., Houghton A. N., Oettgen H. F., Lloyd K. O., Old L. J. Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J Exp Med. 1984 Oct 1;160(4):1219–1233. doi: 10.1084/jem.160.4.1219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. SVENNERHOLM L. THE GANGLIOSIDES. J Lipid Res. 1964 Apr;5:145–155. [PubMed] [Google Scholar]
  26. Tai T., Cahan L. D., Tsuchida T., Saxton R. E., Irie R. F., Morton D. L. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer. 1985 May 15;35(5):607–612. doi: 10.1002/ijc.2910350507. [DOI] [PubMed] [Google Scholar]
  27. Tai T., Paulson J. C., Cahan L. D., Irie R. F. Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci U S A. 1983 Sep;80(17):5392–5396. doi: 10.1073/pnas.80.17.5392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Watanabe T., Pukel C. S., Takeyama H., Lloyd K. O., Shiku H., Li L. T., Travassos L. R., Oettgen H. F., Old L. J. Human melanoma antigen AH is an autoantigenic ganglioside related to GD2. J Exp Med. 1982 Dec 1;156(6):1884–1889. doi: 10.1084/jem.156.6.1884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Yamaguchi H., Furukawa K., Fortunato S. R., Livingston P. O., Lloyd K. O., Oettgen H. F., Old L. J. Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2416–2420. doi: 10.1073/pnas.84.8.2416. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES